Brief: Nicox Announces Last Patients Complete Final Visit In Ncx 470 Phase 3 Mont Blanc Glaucoma Trial

Nicox SA

19/09/2022 06:34

Sept 19 (Reuters) - Nicox SA  NCOX.PA :
    * NICOX ANNOUNCES LAST PATIENTS COMPLETE FINAL VISIT IN NCX
470
PHASE 3 MONT BLANC GLAUCOMA TRIAL
    * LAST PATIENTS COMPLETED THEIR FINAL (3-MONTH) VISIT ON
SEPTEMBER
16
    * 691 PATIENTS WERE ENROLLED IN MONT BLANC TRIAL
    * TOPLINE RESULTS OF MONT BLANC TRIAL DUE I N EARLY NOVEMBER
2022
    * SECOND PHASE 3 TRIAL ON NCX 470, DENALI, IS BEING JOINTLY
CONDUCTED AND EQUALLY FINANCED WITH OUR CHINESE PARTNER,
OCUMENSION THERAPEUTICS. TOPLINE RESULTS IS CURRENTLY EXPECTED
AFTER 2024

Source text for Eikon:  ID:nGNX9ZDRyW 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))